Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Celyad is a biopharmaceutical company, specialized in CAR-T cell therapy, that is ...
Celyad is a biopharmaceutical company, speciali...
MedChain's mission is to use blockchain technology to establish a better, more sec...
MedChain's mission is to use blockchain technol...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a bi...
Tricida, Inc. , Tricida, Inc. , is a pharmaceutical company focused on the develop...
Tricida, Inc. , Tricida, Inc. , is a pharmaceut...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
Join the National Investor Network and get the latest information with your interests in mind.